Product image of Hulio (Adalimumab) supplied by GNH India

Hulio

Active Ingredient:
Adalimumab
Origin:
EU

Hulio (Adalimumab)

Hulio is a prescription biologic medication whose active ingredient is adalimumab, a TNF‑alpha inhibitor delivered as a subcutaneous injection. It is marketed in the European Union and is classified as a biologic disease‑modifying antirheumatic drug (bDMARD). The product is supplied in pre‑filled syringes (strength not specified) for self‑administration under medical supervision.

Manufacturer / TM Owner

Biosimilar Collaborations Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Hulio is indicated for several chronic inflammatory conditions that respond to TNF‑alpha blockade. It is used when conventional therapies have not achieved adequate disease control.

  • Rheumatoid arthritis in adults
  • Psoriatic arthritis and plaque psoriasis
  • Ankylosing spondylitis
  • Moderate to severe Crohn's disease
  • Ulcerative colitis
  • Hidradenitis suppurativa

How It Works

  • Adalimumab is a fully human monoclonal antibody that binds with high affinity to soluble and membrane‑bound tumor necrosis factor‑alpha (TNF‑α). By preventing TNF‑α from interacting with its cell‑surface receptors, the drug interrupts downstream inflammatory signaling pathways, reducing cytokine production, leukocyte activation, and tissue damage associated with autoimmune diseases.

Side Effects

Adalimumab may cause a range of adverse reactions, from mild to severe. Patients should be informed about the most frequently observed events as well as those that require urgent medical attention.

Common

  • Injection‑site pain, redness, or swelling
  • Upper respiratory tract infections
  • Headache
  • Nausea
  • Mild rash or itching

Serious

  • Serious infections (e.g., tuberculosis, fungal infections)
  • Reactivation of hepatitis B
  • Malignancies such as lymphoma
  • Severe allergic reactions (anaphylaxis)
  • Neurological disorders (e.g., demyelinating disease)

Precautions & Warnings

Before starting Hulio, clinicians should evaluate patient history and monitor for potential complications throughout therapy.

  • Screen for latent tuberculosis and hepatitis B infection
  • Assess for active infections; defer treatment if present
  • Evaluate for a history of malignancy or demyelinating disease
  • Use caution in patients with congestive heart failure
  • Monitor complete blood counts and liver function periodically
  • Discuss vaccination status; avoid live vaccines during treatment

Avoid Interactions

Adalimumab can influence the activity of other medicines, and some agents may affect its safety profile.

Avoid

  • Live attenuated vaccines (e.g., measles, varicella)
  • Concurrent use of other biologic immunosuppressants without specialist guidance

Use with caution

  • Systemic corticosteroids and other immunosuppressants (e.g., methotrexate)
  • Antifungal agents (e.g., azoles)
  • Antiviral therapies for hepatitis B
  • Drugs that prolong QT interval (monitor cardiac status)
  • Vaccines containing inactivated organisms (administer before starting therapy)

Frequently Asked Questions

Hulio is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate to severe Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

Hulio is supplied as a pre‑filled syringe for subcutaneous injection, typically given by the patient or a caregiver under the guidance of a healthcare professional.

Methotrexate is often combined with adalimumab to improve efficacy, but the combination should be managed by a specialist to monitor for increased infection risk.

Patients should be screened for latent tuberculosis, hepatitis B infection, and active infections. Baseline blood counts and liver function tests are also recommended.

Live vaccines are contraindicated during treatment with Hulio because the drug suppresses immune function and may increase the risk of vaccine‑derived infection.

Typical injection‑site reactions include mild pain, redness, swelling, or itching at the site of administration and usually resolve without medical intervention.

By inhibiting TNF‑α, Hulio can increase susceptibility to bacterial, fungal, and viral infections, including reactivation of latent tuberculosis and hepatitis B.

The safety of Hulio during pregnancy has not been fully established; treatment decisions should be made by a specialist weighing potential benefits and risks.

Regular monitoring includes clinical assessment for infections, periodic blood counts, liver enzymes, and screening for signs of malignancy or demyelinating disease.

No direct pharmacokinetic interaction is known, but clinicians should monitor for bleeding if patients develop infections or require invasive procedures.

They should seek immediate medical attention, as severe reactions such as anaphylaxis require emergency treatment and discontinuation of the drug.

Current guidelines do not require routine dose adjustments for mild to moderate renal or hepatic impairment, but clinical judgment is advised for severe organ dysfunction.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Adalimumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT